| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-71 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 |
| filingDate |
2014-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e9befd6d6c08cde4b8e37c53efdc6c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b754b9091ced7df0576213d9722c20e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_027b02953f27c8fe8bf305ffa3b10a8d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_478567d1e0f8ffcb13f68964bdbe9cc9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2752710b88845f841d800e2e18de2144 |
| publicationDate |
2021-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20210094669-A |
| titleOfInvention |
Human fcrn-binding modified antibodies and methods of use |
| abstract |
The present application reports the use of an antibody comprising an Fc-region with abolished FcRn binding for transporting a soluble receptor ligand from the eye across the blood-ocular-barrier into the blood circulation. |
| priorityDate |
2013-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |